Stone Shi

466 Flips | 3 Magazines | 12 Likes | 2 Following | 9 Followers | @stone_dh_shi | Keep up with Stone Shi on Flipboard, a place to see the stories, photos, and updates that matter to you. Flipboard creates a personalized magazine full of everything, from world news to life’s great moments. Download Flipboard for free and search for “Stone Shi”

Better Buy: Biogen Inc. vs. Amgen

Biogen and Amgen have been two of the best performing biotechs for a decade. But one stock clearly has an easier path toward value creation.<p>Top …

Amgen

Amgen resubmits U.S. marketing application for osteoporosis med Evenity

Amgen (NASDAQ:AMGN) has refiled its U.S. marketing application seeking approval for EVENITY (romosozumab) for the treatment of osteoporosis in …

Eli Lilly

The FDA just approved a new kind of medication that could change the way we treat a condition that affects 38 million Americans

The FDA just approved a migraine treatment that's the first of a new class of medications.<p>The drug is called Aimovig, and it's made by Amgen in partnership with Novartis. It will cost $6,900 a year.<p>The wave of new treatments, of which Aimovig is the first to get approval, are going after the huge …

FDA Approves Amgen's Migraine Drug

The U.S. Food and Drug Administration has approved Amgen’s erenumab (which it’s calling Aimovig) to prevent migraines.<p>“We feel pretty strongly this is a huge opportunity to help patients with a targeted, migraine specific medication that’s broadly efficacious, and can be administered in a …

Amgen's (AMGN) CEO Bob Bradway on Q1 2018 Results - Earnings Call Transcript

Amgen Inc. (NASDAQ:AMGN) Q1 2018 Earnings Conference Call April 24, 2018 5:00 PM ET<p><b>Executives</b><p>Arvind Sood – Vice President-Investor Relations<p>Bob …

New Analyses Presented At AHA 2017 Show Repatha® (evolocumab) Significantly Reduced Cardiovascular Events In Patients With Peripheral Artery Disease And In Patients With A History Of Heart Attacks

<b>Data Support Use of Repatha to Reduce Risk of Recurrent Cardiovascular Events in Patients With History of Multiple Heart Attacks</b><p><b>Additional Analysis</b> …

Amgen Price Target Trimmed After Major Product Sales Disappoint In Q3

BMO Capital's Ian Somaiya decreased his price target for <b>Amgen, Inc.</b> (NASDAQ: AMGN) from $198 to $192 while maintaining his Market Perform rating in …

Amgen Discontinues Quest for New CETP Heart Drug

In 2015, <b>P.K. Shah</b>, director of atherosclerosis research at <b>Cedars-Sinai Heart Center</b> in Los Angeles, declared that <b>CETP inhibitors were “dead”</b> as …

Mylan Receives CRL for Neulasta Biosimilar

- By Alberto Abaterusso<p><b>Mylan NV</b> (MYL) - the U.K.-headquartered health care company that is engaged in the development, production and global …

New trial ordered in Sanofi/Regeneron fight with Amgen over PCSK9 inhibitor patents

An appeals court has ordered a new trial in Amgen's (AMGN -1.5%) dispute with Sanofi (SNY +0.5%) and Regeneron (REGN +4.4%) over patents related to …

Regeneron Pops After Judge Tosses Ban On Amgen-Rivaling Med

<b>Regeneron Pharmaceuticals</b> (REGN) and <b>Amgen</b> (AMGN) stocks diverged early Thursday after a U.S. appellate court tossed out a ban on sales of Regeneron …

Sanofi and Regeneron, seeking to shield Dupixent, lose first IPR try against Amgen

To defend against Amgen’s claim that Sanofi and Regeneron had infringed one of its patents with new atopic dermatitis rollout Dupixent, the …

AbbVie and Amgen settle Humira patent dispute

AbbVie (NYSE:ABBV) and Amgen (NASDAQ:AMGN) have agreed to settle their litigation over the latter's planned biosimilar to HUMIRA (adalimumab). Under …

The FDA Just Set The Stage For Amgen, Fueled By A Milestone Biosimilar Approval

In many regards it was the shot heard 'round the biopharma world, even if most investors didn't hear, or care if they did hear it. What's that? On …

Cost-effectiveness of Evolocumab Therapy in Patients with ASCVD

This study evaluates the cost-effectiveness of evolocumab in patients with atherosclerotic cardiovascular disease when added to standard background …

New Economic Analysis Based On Repatha® (Evolocumab) Outcomes Data Published In JAMA Cardiology

<b>Repatha Used in Patients at High-Risk For Cardiovascular Events is Cost-Effective at Net Prices at or Below $9,669</b><p>THOUSAND OAKS, Calif., Aug. 23, …

Amgen's cholesterol drug is cost-effective at $10,000 a year: study

Amgen Inc.'s AMGN, -1.30% cholesterol-lowering drug Repatha is cost-effective for high-risk patients at a yearly net price of $9,669 or below, …

Amgen

PCSK9 inhibitors still too pricey, study finds

Dive Brief:<p>New research published online Tuesday found Amgen, Inc.'s Repatha would need significant price reductions in order to meet a measure of …

Tournaments

<b>2018 Practice Tournaments:</b> <br>For questions or registrations, please contact the organizer directly.<p><b>Curtis School, Los Angeles - October 20</b><b><br>Contacts</b>: …

Market Realist

Our website is made possible by displaying online advertisements to our visitors.<br>Please consider supporting us by disabling your ad blocker.

US regulators turn away Amgen/UCB’s bone drug Evenity

Amgen and UCB’s application to market bone-boosting drug Evenity as a treatment for postmenopausal women with osteoporosis has hit a setback, having …

Cost watchdog, citing Repatha outcomes shortfall, pitches lower price for Amgen PCSK9

PCSK9 drug makers and their pharma peers have hit out at the Institute for Clinical and Economic Review, arguing that the self-appointed cost …

Amgen's Multiple Myeloma Drug Receives NICE Recommendation

<b>Amgen Inc.</b> AMGN announced that Kyprolis gained recommendation from National Institute for Health and Care Excellence (NICE) in combination with …

U.S. Supreme Court speeds copycat biologic drugs to market

(Adds comment from Novartis, Amgen, paragraphs 5-6)<p>By Andrew Chung<p>WASHINGTON, June 12 (Reuters) - The U.S. Supreme Court on Monday cut the time it …

Sanofi/Regeneron unveil more positive data for PCSK9 inhibitor

Sanofi and Regeneron have unveiled new data further backing the safety and efficacy of PCSK9 inhibitor Praluent in lowering cholesterol in patients …

FDA rejects Coherus's biosimilar for Neulasta, shares plunge

* FDA does not ask Coherus for additional trial<p>* Coherus predicts roughly one-year delay<p>* Coherus shares tumble 30 pct, Amgen up slightly (Adds …